If you’ve read our blog post on the @SanofiUS response to Roseanne Barr’s mention of one of its drugs then you know the basics of the story and the overall conversation volumes. Here, PR Week includes some statements from Sanofi US about the quick turnaround and the necessity of the response.
“Our view is that using our medicines as a crutch for bad behavior is not appropriate,” said [Angela Bechan, head of communications for North America at Sanofi]. “It comes down to our core values at Sanofi: we take diversity and inclusion very seriously. It is part of how we work every day.”
About the speed of turnaround, Bechan said:
“It was not a big leap for anyone to consider that this was the right thing to do because it is consistent with how we work as a company and with the way we feel here.”
Real-time social for pharma companies isn’t easy, and it requires all the regular consultation, but it can be done.